• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Glucocorticoid compounds improve stem cell transplant efficiency in mice [PreClinical]

byCorinne FoleyandJessica Lau
April 25, 2017
in Chronic Disease, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. Following treatment with glucocorticoids, human hematopoietic stem cells (HSCs) from cord blood demonstrated enhanced homing and engraftment to bone marrow in mice.

2. Glucocorticoids improved HSC homing by increasing histone acetylation, which resulted in increased CXCR4 expression.

Evidence Rating Level: 2 (Good)

Study Rundown: HSCs from cord blood are used for hematopoietic cell transplantation to treat hematological disorders, but their low engraftment in the bone marrow remains a challenge. Because the CXCR4 protein is known to be involved in stem cell migration to the bone marrow, this study evaluated compounds that increased HSC expression of CXCR4.

A variety of compounds was tested to determine their effect on cord blood cell expression of CXCR4. This screen found that dexamethasone, a glucocorticoid, enhanced CXCR4 expression. When other glucocorticoids were tested, fluticasone propionate (Flonase) led to the greatest increase in CXCR4 expression. The effect of Flonase on stem cell transplantation was tested in mice. After human cord blood cells were treated with Flonase, they showed increased migration and engraftment in mouse bone marrow. The researchers then determined the mechanism through which glucocorticoids function. It was found that these compounds enhanced the acetylation of histones associated with the CXCR4 gene, leading to enhanced gene transcription.

By showing both the efficacy and underlying mechanism of glucocorticoid treatment in stem cell transplantation, this study demonstrated the potential of this therapeutic approach. Since glucocorticoids are an established treatment for a variety of conditions, their safety is has been evaluated. The optimal dose of these compounds as well as the clinical benefit of treated stem cells still need to be assessed, but this study presents a potential means to overcome the challenges of cord blood stem cell transplantation.

RELATED REPORTS

Genetically modified porcine-to-human cardiac xenograft failure

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

Click to read the study in Nature Medicine

Relevant Reading: Improving quality and potency testing for umbilical cord blood: A new perspective

In-Depth [animal study]: A nuclear receptor ligand library of 74 compounds was screened for the ability to increase CXCR4 expression of human cord blood CD34+ cells. This screen identified dexamethasone as the only compound to have a significant effect. When other glucocorticoids including methylprednisolone, hydrocortisone, and Flonase were tested, Flonase resulted in the greatest increase in CXCR4 expression (p<0.001).

Human cord blood CD34+ cells were then treated for 16 hours with Flonase and injected into irradiated immunodeficient NSG mice. Treated cells showed a 4.4-fold increase in homing efficiency as well as increased HSC engraftment after 4 months (p<0.05). The treated CD34+ cells from these transplanted mice were then isolated and introduced into secondary recipient NSG mice to determine whether they showed similar properties. Enhanced engraftment was noted in the secondary recipients as well (p<0.05), demonstrating the potential long-term efficacy of this treatment.

Real-time PCR demonstrated that Flonase treatment of human cord blood CD34+ cells led to an increase in CXCR4 mRNA levels (p<0.001). Chromatin immunoprecipitation analysis demonstrated enrichment for glucocorticoid receptors in the region of the CXCR4 promoter, leading to the examination of histone alteration in this region. Flonase treatment led to increased acetylation of lysines 5 and 16 on histone H4 (p<0.001), with no effect on histone H3, indicating the specific targeting of this drug to the CXCR4 promoter region.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: stem cellsteroidtransplant
Previous Post

2 Minute Medicine Rewind April 24, 2017

Next Post

Direct-acting antiviral therapy for hepatitis C virus associated with hepatitis B virus reactivation in co-infected patients

RelatedReports

Image-guided percutaneous drainage of pericardial effusions is safe and effective
Cardiology

Genetically modified porcine-to-human cardiac xenograft failure

July 11, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection
StudyGraphics

#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

January 5, 2022
#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years
StudyGraphics

#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years

October 29, 2021
Next Post
Spleen elastography may be effective in the diagnosis of portal hypertension

Direct-acting antiviral therapy for hepatitis C virus associated with hepatitis B virus reactivation in co-infected patients

Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED

Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED

Mindfulness offers short-term relief from low back pain

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Combined genetic testing of cardiomyopathies and arrhythmias increases diagnostic yield to inform patient management
  • Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial
  • Genetic risk for hemochromatosis associated with abnormal iron deposition localized to motor circuits of the brain
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.